News for Beam Therapeutics Inc. (BEAM)

We have all heard the old saying, “A penny makes a dime,” highlighting the idea that every little effort counts toward a bigger goal.

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) and set a price target of $80.00. The analyst based the optimistic rating on the company’s gene editing pipeline, […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is among the best growth stocks to invest in for the next 5 years. The General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), David O. Watson, sold 5,000 shares of common stock for $18.77, higher than the current trading price of $17.62. This transaction, worth $93,850, although it follows a challenging period, […]

The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio.

Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks.

Cathie Wood's Ark Invest bought Shopify shares worth $4.11 million, while selling $4.63 million of Robinhood stock on Wednesday June 25, 2025 . Other notable trades were also made.

Ark Invest made strategic acquisitions of Shopify and Airbnb, reflecting its interest in high-growth tech and e-commerce sectors on Tuesday June 24, 2025.

Beam reports breakthrough results from BEAM-101's early-stage trial for severe sickle cell disease. Read more here.

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Beam Therapeutics (NASDAQ:BEAM) gains FDA orphan drug status for BEAM-101 to treat sickle cell disease. Read more here.

**media[644200]**

Beam Therapeutics (BEAM) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting orphan drug designation to its investiga

Summary Beam Therapeutics Inc (BEAM), a biotechnology company specializing in precision genetic medicines, announced on May 29, 2025, that the U.S. Food and Dru

Beam Therapeutics (BEAM) has received orphan drug designation from the FDA for its innovative treatment candidate, BEAM-302. This experimental therapy utilizes

Beam Therapeutics faces slow pipeline progress and high R&D costs despite a $500M cash boost. Learn why patience is key for investors.

Beam Therapeutics, identified by the stock ticker BEAM, has achieved a significant milestone with the U.S. Food and Drug Administration granting orphan drug des

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. ( BEAM), a biotechnology company developing precision genetic medicines through base

Wells Fargo's analyst, Yanan Zhu, has adjusted the price target for Beam Therapeutics (BEAM), reducing it from $75 to $70, while maintaining an Overweight ratin

**media[617224]**